21 preventive and therapeutic effects of plant polyphenols through suppression of ... · 2014. 1....

DK4416_book.fm Page 243 Wednesday, July 27, 2005 12:44 PM

21
Preventive and Therapeutic Effects of Plant Polyphenols through Suppression of Nuclear Factor-Kappa B
Navindra P. SeeramUCLA, Los Angeles

Haruyo Ichikawa, Shishir Shishodia, and Bharat B. AggarwalUniversity of Texas, Houston

CONTENTS

21.1 Overview..................................................................................................24321.2 Introduction..............................................................................................24421.3 NF-κB and Disease .................................................................................24421.4 NF-κB as a Therapeutic Target ...............................................................245Acknowledgments .............................................................................................262Abbreviations ....................................................................................................263References .........................................................................................................264

21.1 OVERVIEW

Nuclear transcription factor-κB (NF-κB) regulates the expression of over 200different genes. The activation of NF-κB has now been linked with a variety ofinflammatory diseases, including cancer, atherosclerosis, myocardial infarction,diabetes, allergy, asthma, arthritis, Crohn’s disease, multiple sclerosis, Alzhe-imer’s disease, osteoporosis, psoriasis, septic shock, and AIDS. There is muchevidence suggesting that phytochemicals can inhibit the pathways that lead to theactivation of this transcription factor and have the potential to prevent and treat

243

244

Molecular Interventions in Lifestyle-Related Diseases

AU: ChangeOK?


the diseases mentioned. These phytochemicals are derived from plants such asturmeric, red pepper, cloves, ginger, cumin, anise and fennel, rosemary, garlic,green tea, basil, cauliflower, cabbage, artichoke, lemon, and pomegranate.

21.2 INTRODUCTION

Plant extracts and natural compounds purified from plants have been used byhumans for many centuries for the treatment and alleviation of a variety ofinflammation-related diseases, including cancer. Eastern medicine, viz., tradi-tional Chinese medicine (TCM) and the Indian ayurvedic system of medicine,continue to prescribe complex mixtures of herbs and herbal extracts for thetreatment of cancer. Recent research has shown that a mechanism-based approachthat targets the means by which cancer cells prosper has significant advantagesover the current methods of cancer treatment, including chemotherapy, with theirattendant adverse effects. The regulation of the cell cycle (cell survival, prolifer-ation, and death) requires the integration of a myriad of cell-signaling factors,including those that direct the transcription of genes coding for integral cellproteins. Nuclear factor (NF)-κB is a transcription factor that regulates the expres-sion of genes involved in cancer and other diseases.

21.3 NF-κκκκB AND DISEASE

NF-κB, discovered by David Baltimore in 1986, is a ubiquitous factor that residesin the cytoplasm in an inactive state. When activated, it is translocated to thenucleus and induces gene transcription. NF-κB is activated by free radicals,inflammatory stimuli, carcinogens, tumor promoters, endotoxins, gamma radia-tion, UV light, and x-rays. On activation, it induces the expression of more than200 genes, and these genes have been shown to suppress apoptosis and inducecellular transformation, proliferation, invasion, metastasis, chemoresistance,radioresistance, and inflammation.1–3 The activated form of NF-κB has been foundto mediate cancer,1,4,5 atherosclerosis,6 myocardial infarction,7 diabetes,8 allergy,9,10

asthma,11 arthritis,12 Crohn’s disease,13 multiple sclerosis,14 Alzheimer’s disease,15,16

osteoporosis, psoriasis, septic shock, AIDS, and other inflammatory diseases17–19

(Figure 21.1). That NF-κB has been linked to wide variety of diseases is not toosurprising because most diseases are caused by dysregulated inflammatory mech-anisms.20 Thus, agents that can suppress NF-κB activation can, in principle, eitherprevent, delay the onset, or treat NF-κB -linked diseases.

Ever since research has shown that there is an intrinsic link between inflam-mation and various diseases, it has become obvious that inhibition of NF-κBactivity is desirable in the treatment of not only inflammation but also the diseaseitself. For instance, aberrant NF-κB activation is a known factor in oncogenesis,tumor growth, and metastasis, and specific constitutive activation of NF-κB hasbeen identified in a number of cancers including, breast, ovarian, colon, andprostate cancer and Hodgkin’s lymphoma (for references see Reference 1). Hence,

Preventive and Therapeutic Effects of Plant Polyphenols

245

AU: Chaptertitle needs tobe reduced in running head to fit. Pls. check wording.


this transcription factor is an important target in the prevention of diseases andtheir treatment in humans.

21.4 NF-κκκκB AS A THERAPEUTIC TARGET

NF-κB represents an important and very attractive therapeutic target for plant-derived polyphenols. Much attention has been paid in the last decade to theidentification of compounds that selectively interfere with this pathway. Morerecently, a great number of plant-derived natural products have been evaluatedas possible inhibitors of the NF-κB pathway (Table 21.1, Figure 21.2). Thischapter focuses on plant extracts, plant isolates, and distinct classes of plant-derived compounds that form part of this group. It is noteworthy that there arealso reports of synthetic compounds and compounds from nonplant sources (e.g.,caffeic acid phenethyl ester [CAPE] identified from honey bee propolis) that areknown to block the activity of NF-κB21.

NF-κB plays a central role in inflammation, and research has made it clearthat most diseases are linked to inflammation. Because NF-κB can also regulatethe expression of many key genes involved in a variety of human cancers, itrepresents a relevant and promising target for new therapeutic agents. Manypharmaceutical and biotechnology companies have drug discovery programs thattarget NF-κB and have been investing heavily in the search for proteins thatregulate this transcription factor. However, due to the ubiquitous nature of NF-κB,many of these drugs may exhibit undesirable side effects.

The mechanism-based approach to combat diseases from different angleswith combinations of naturally derived compounds has a distinct advantage in

FIGURE 21.1 NF-κB-linked diseases.

Heart failure

Atherosclerosis

Boneresorption

Multiple sclerosis

Muscular dystrophy

Cardiachypertrophy

Ischemia/Reperfusion

Chronic obstructive pulmonary disease

Systemic inflammatory response syndrome

Inflammatorybowel disease

Neurological disease

Arthritis

AIDS

Asthma

Lupus

Cancer

Viral infections

Diabetes

Alzheimer’sdisease

Incontinentia pigmenti

NF-κκκB

246



TAB

LE 2

1.1

Nat

ural

Pro

duct

s fr

om P

lant

s th

at E

xhib

it C

hem

opre

vent

ive

and

Ther

apeu

tic

Act

ivit

ies

agai

nst

Can

cer

Com

poun

dSo

urce

Bot

anic

al N

ame

Stru

ctur

e↓↓↓↓ N

F-κκκκ B

PT

Ref

.

Poly

phen

ol

Am

ento

flavo

ne

(bia

pige

nin)

* G

ingk

oG

ingk

o bi

loba

; C

ypre

ss s

pp.;

G

aleo

bdol

on c

hine

nse;

Gar

cini

a in

term

edia

; Se

lagi

nell

a sp

p.;

Bio

phyt

um s

ensi

tivu

m

+—

—22

,23

Api

geni

n*

Frui

ts a

nd v

eget

able

sSc

utel

lari

a sp

p. (

incl

. in

Chi

nese

he

rbal

mix

ture

, PC

SPE

S, H

uang

-Qi;

Q

ingk

aili

ng; S

huan

ghua

ngli

an e

tc.)

; C

iris

ium

spp

.; C

rota

lari

a sp

p.;

Que

rcus

nut

gall

;Mat

rica

ria

recu

tita

; Sa

ussu

rea

med

usa;

Lan

tana

m

onte

vide

nsis

Bri

q.

4′,5

,7-T

rihy

drox

yflav

one

+—

—24

–26

Arc

tigen

in*

and

dem

ethy

ltrax

illag

enin

Arc

tium

lap

pa;

Cen

taur

ea s

pp.;

To

rrey

a nu

cife

ra+

——

27

Aur

apte

neC

itrus

fru

its (

hass

aku,

gr

apef

ruit,

nat

udai

dai)

Cit

rus

spp.

7-G

eran

yl-o

xyco

umar

in—

——

28

Bai

cale

in*

and

its

deri

vativ

esa

Skul

lcap

Scut

ella

ria

spp.

(in

clud

ed i

n C

hine

se

herb

al m

ixtu

re, P

CSP

ES,

Hua

ng-Q

i;

Qin

gkai

ling

; Sh

uang

huan

glia

n, e

tc.)

5,6

,7-T

rihy

drox

yflav

one

++

+29

–31

Blu

eber

ry a

nd b

erry

mix

Blu

eber

ry, b

lack

cur

rant

, ra

spbe

rry,

str

awbe

rry

Rub

us s

pp.;

Vac

cini

um s

pp.;

Fra

gari

a an

anas

sa+

——

32–3

4

Can

nabi

nol*

Hem

p se

ed o

il,

mar

ijuan

a C

anna

bis

spp.

6,6,

9-T

rim

ethy

l-3-

pent

yl-6

H-

dibe

nzo[

b,d]

pyra

n-1-

ol;

+—

+35

–37

-

AU

: Wha

t do

es th

is

sym

bol i

ndi-

cate

?

AU

: Sho

uld

this

be

“com

pone

nt o

f”?

AU

: Sho

uld

this

be

“and

ot

her

ber-

ries”

?


247


Cat

alpo

side

*C

atal

pa s

pp.;

Ver

onic

a sp

p.O

xire

no[4

,5]c

yclo

pent

a[1

,2-c

]pyr

an-β

-D-

gluc

opyr

anos

ide

+—

—38

Cat

echi

ns*

(and

th

eafla

vins

*)b

Gre

en t

ea (

incl

udin

g fe

rmen

ted,

i.e

., bl

ack

teas

), s

potte

d kn

apw

eed,

she

a ke

rnel

s, c

ocoa

Cam

elli

a si

nens

is;

Cen

taur

ea m

acul

osa;

Vit

ella

ria

para

doxa

; T

heob

rom

a ca

cao

3′,4

′,5,7

-Tet

rahy

drox

y-2,

3-tr

ans-

flava

n-3-

ol+

++

39–4

1

Cir

sim

ariti

n*B

asil,

sag

e, r

osem

ary

Cir

sium

mar

itim

um;

Oci

mum

sa

nctu

m;

Salv

ia o

ffici

nali

s;

Ros

mar

inus

offi

cina

lis

5,4′

-Dih

ydro

xy-6

,7-

dim

etho

xyfla

vone

——

—42

Cur

cum

in*

Tur

mer

ic (

hald

i)C

urcu

ma

long

aD

ifer

uloy

lmet

hane

++

+—

Ella

gic

acid

*St

raw

berr

ies,

ra

spbe

rrie

s,

blac

kber

ries

, ba

yber

ries

, fu

ejio

a,

pom

egra

nate

s,

pine

appl

e, w

alnu

ts

Fra

gari

a an

anas

sa;

Rub

us

idae

us;P

unic

a gr

anat

um;

Jugl

ans

regi

a

4,4′

,5,5

′,6,6

′-Hex

ahyd

roxy

-di

phen

ic a

cid

dila

cton

e—

——

34,4

4

Em

odin

*A

loe

vera

Po

lygo

num

spp

.; C

assi

a sp

p.;

Glo

ssos

tem

on b

rugu

ieri

(m

ogha

t);

Rhe

um s

pp.

(rhu

barb

); H

oven

ia

acer

ba

3-M

ethy

l-1,

6,8-

Tri

hydr

oxy-

anth

raqu

inon

e+

+—

45

Flav

opir

idol

c5,

7-D

ihyd

roxy

-8-(

4-N

-met

hyl-

2-hy

drox

ypyr

idyl

)-6′

-ch

loro

flavo

ne h

ydro

chlo

ride

+—

—46

Gen

iste

in*

Soyb

eans

, ch

ickp

ea,

kudz

u ro

otG

lyci

ne m

ax;

Cic

er a

riet

inum

; P

uera

ria

loba

ta r

adix

; D

esm

odiu

m

spp.

3-(4

-Hyd

roxy

phen

yl)-

5,7-

dihy

drox

y-ch

rom

en-4

-one

++

+47

,48

Glo

ssog

yne

tenu

ifol

iad

Her

bG

loss

ogyn

e te

nuif

olia

+—

—49

248



TAB

LE 2

1.1

(con

tinu

ed)

Nat

ural

Pro

duct

s fr

om P

lant

s th

at E

xhib

it C

hem

opre

vent

ive

and

Ther

apeu

tic

Act

ivit

ies

agai

nst

Can

cer

Com

poun

dSo

urce

Bot

anic

al N

ame

Stru

ctur

e↓↓↓↓ N

F-κκκκ B

PT

Ref

.

Hem

atei

n*N

atur

al d

ye f

rom

lo

gwoo

d+

——

50,5

1

Hes

peri

dine

Ora

nges

Cit

rus

spp.

Hes

peri

tin-7

-rut

inos

ide

——

—52

HM

P*B

lack

fru

it or

gal

anga

lA

lpin

ia s

pp.

7-(4

′-Hyd

roxy

-3′-

met

hoxy

phen

yl)-

phen

ylhe

pten

one

+—

—53

Hyp

eric

in*

St.

John

’s w

ort

Hyp

eric

um s

pp.

++

+54

,55

Isot

hym

usin

Bas

ilO

cim

um s

pp.;

Lim

noph

ila

geof

fray

i;

Bec

ium

gra

ndifl

orum

6,7-

Dim

etho

xy-5

,8,4

′-tr

ihyd

roxy

flavo

ne—

——

56

Isom

allo

toch

rom

anol

* an

d is

omal

loto

chro

men

e

Mal

lotu

s ja

poni

cus

+—

—57

Kae

mpf

erol

Frui

ts a

nd v

eget

able

s e.

g.,

tom

ato,

oni

ons

Lyco

pers

icon

esc

ulen

tum

, G

inkg

o bi

loba

3,5,

7,4′

-Tet

rahy

drox

yflav

one

——

—58

Lut

eolin

*Fr

uits

and

veg

etab

les,

te

a C

amel

lia

sine

nsis

; Sc

utel

lari

a sp

p. 2

-(3,

4-D

ihyd

roxy

phen

yl)-

5,7-

dihy

drox

y-ch

rom

en-4

-one

+

——

25,5

9

Mor

inG

uava

, al

mon

d P

sidi

um g

uaja

va;

Pru

nus

dulc

is

2′,3

,4′,5

,7-P

enta

hydr

oxy-

flavo

ne—

++

60

Myr

icet

inFr

uits

and

veg

etab

les

2-(3

,4-5

-Tri

hydr

oxyp

heny

l)-

3,5,

7-T

rihy

drox

y-ch

rom

en-

4-on

e

——

—61

AU

: Wha

t do

es th

is

sym

bol i

ndi-

cate

?


249


Nas

unin

Egg

plan

tSo

lanu

m m

elon

gena

Del

phin

idin

-3-(

p-co

umar

oylr

utin

osid

e)-

5-gl

ucos

ide

——

—62

Nob

iletin

Citr

usC

itru

s sp

p.5,

6,7,

8,3′

,4′-H

exam

etho

xy

flavo

ne—

——

28

Nor

dihy

drog

uaia

retic

ac

id*

Gua

iacu

m o

ffici

nale

+—

—63

Och

na m

acro

caly

x ex

t.O

chna

mac

roca

lyx

+—

—64

Oen

othe

in B

Oen

othe

ra s

pp.;

Eug

enia

uni

flora

Hyd

roly

zabl

e el

lagi

tann

in—

——

65Pa

ndur

atin

AK

aem

pfer

ia p

andu

rata

+—

—66

Proc

yani

dins

Tea,

cra

nber

ries

, ap

ple,

gr

ape

seed

s, p

ear

Cam

elli

a si

nens

is, V

acci

num

spp

.;

Pru

nus

spp.

C

onde

nsed

tan

nins

——

—67

Purp

urog

allin

Que

rcus

sp.

Nut

gall

2,3,

4,6-

Tetr

ahyd

roxy

-5H

-be

zocy

cloh

epte

n-5-

one

——

—68

,69

Pycn

ogen

olM

ariti

me

pine

bar

k ex

trac

tP

inus

mar

itim

a B

iofla

vano

id e

xtra

ct+

——

70,7

1

Que

rcet

inFr

uits

and

veg

etab

les

Mal

us s

pp.;

Lyc

oper

sico

n es

cule

ntum

2-

(3,4

-Dih

ydro

xyph

enyl

)-3,

5,7-

trih

ydro

xy-c

hrom

en-

4-on

e

+—

—72

Rhe

inD

ayli

lies

(H

emer

ocal

lis

spp.

); R

heum

of

ficin

ale

(dah

uang

)1,

8-D

ihyd

roxy

-3-

carb

oxya

nthr

aqui

none

+—

—73

Sang

geno

n C

*M

ulbe

rry

Mor

us s

pp.

+—

—74

Sily

mar

ine

Milk

thi

stle

, ar

ticho

kes

Sily

bum

mar

ianu

m;

Cyn

ara

scol

ymus

Flav

onol

igna

n ex

trac

t+

++

75,7

6,77

Sa

ucer

neol

s*,

sauc

hino

ne,

and

man

assa

ntin

s*

Saur

urus

spp

.+

——

78,7

9

Tang

eret

inci

trus

fru

itsC

itru

s sp

p.5,

6,7,

8,4′

-Pen

tam

etho

xyfl

avo-

ne—

——

80

250 Molecular Interventions in Lifestyle-Related Diseases


TAB

LE 2

1.1

(con

tinu

ed)

Nat

ural

Pro

duct

s fr

om P

lant

s th

at E

xhib

it C

hem

opre

vent

ive

and

Ther

apeu

tic

Act

ivit

ies

agai

nst

Can

cer

Com

poun

dSo

urce

Bot

anic

al N

ame

Stru

ctur

e↓↓↓↓ N

F-κκκκ B

PT

Ref

.

Wed

elol

acto

ne*

Wed

elia

spp

.; E

clip

ta a

lba

1,8,

9-T

rihy

drox

y-3-

met

hoxy

- 6H

-ben

zofu

ro[3

,2][

1]-

benz

opyr

an-6

-one

,

+—

—81

Yak

uchi

none

s* A

and

BA

lpin

ia o

xyph

ylla

1-(4

′-Hyd

roxy

-3′-

met

hoxy

phen

yl)-

7-ph

enyl

-3-

hept

anon

e,1-

(4′-h

ydro

xy-3

′-m

etho

xyph

enyl

)-7-

phen

ylhe

pt-1

-en-

3-on

e

+—

—82

Terp

enes

And

alus

ol*

Side

rite

s fo

eten

s+

——

83A

neth

ol*f

and

ana

logs

Bro

ccol

i, an

ise,

clo

ves,

ca

shew

B

rass

ica

oler

acea

; ll

licu

m v

erum

; O

cim

um sp

p.; S

yzyg

ium

aro

mat

icum

; A

naca

rdiu

m o

ccid

enta

le;

Hib

iscu

s sa

bdar

iffa

4-M

etho

xypr

open

ylbe

nzen

e+

++

84,8

5

Art

emis

inin

(qin

ghao

su)

Art

emis

ia a

nnua

L.

spp.

+—

—86

Avi

cins

*gA

casi

a vi

ctor

iae

+—

—87

Aza

dira

chtin

hN

eem

tre

eA

zadi

rach

ta i

ndic

a, A

. Ju

ssie

u—

——

88β-

caro

tene

Car

rot,

citr

us f

ruits

, pu

mpk

inD

aucu

s ca

rota

sat

ivus

; C

itru

s un

shiu

m

ar;

Cur

curb

ita

mos

chat

a—

——

89,9

0

β-cr

ypto

xant

hin

Frui

tsC

aric

a pa

paya

L.

Phy

sali

sβ,

β-C

arot

en-3

-ol

——

—89

,91

Bak

uchi

ol (

drup

anol

)*B

emch

i se

eds

Pso

rale

a co

ryli

foli

a (b

emch

i);

Oth

olob

ium

pub

esce

ns

4-(3

-eth

enyl

-3,7

-dim

ethy

l-1,

6-oc

tadi

enyl

)-ph

enol

+

——

92

AU

: Wha

t do

es th

is

sym

bol i

ndi-

cate

?

Preventive and Therapeutic Effects of Plant Polyphenols 251


Bet

ulin

ic a

cid*

Bir

ch t

ree,

alm

ond

hulls

Bet

ula

spp.

; Q

uisq

uali

s F

ruct

us;

Cou

ssar

ea p

anic

ulat

a; A

lang

ium

la

mar

ckii

3-β-

Hyd

roxy

-1up

-20(

29)e

n-28

-aci

d+

——

93

Car

noso

l*R

osem

ary,

sag

eR

osm

arin

us o

ffici

nali

s; S

alvi

a of

ficin

alis

2H

-9,4

a-(e

poxy

met

hano

)-ph

enan

thre

n-12

-one

+—

—94

Cel

astr

ol*

Cel

astr

us o

rbic

ulat

us+

——

95C

ostu

nolid

e*M

agno

lia

gran

diflo

ra;

Tso

ongi

oden

dron

odo

rum

; Sa

ussu

rea

lapp

a

+—

—96

Cuc

urbi

taci

nsi

Cuc

urbi

tace

aeC

ucur

bita

and

rean

a; T

rich

osan

thes

ki

rilo

wii

; E

laeo

carp

us m

aste

rsii

3-β-

(β-D

-Glu

cosy

loxy

)-16

-,23

-α-e

poxy

cucu

rbita

-5,

24-d

iene

-11-

one

——

—97

,98

Erg

olid

e*In

ula

spp.

Dih

ydro

bige

lovi

n+

——

99E

xcis

anin

A*

Isod

on (

Rab

dosi

a) s

pp.

+—

—10

0Fo

liol*

Side

riti

s sp

p.+

——

101

Ger

mac

rano

lides

*j an

d E

udes

man

olid

es

Car

pesi

um d

ivar

icat

um;

Mon

tano

a hi

bisc

ifol

ia+

——

102,

103

Gin

kgo

bilo

ba e

xt.

Gin

gko

bilo

ba+

——

104

Gin

seno

side

Rg3

*Pa

nax

spp.

+—

—10

5G

lycy

rrhi

zin*

Lic

oric

e ro

otG

lycy

rrhi

za g

labr

a; G

lycy

rrhi

za

ural

ens

+—

—10

6

Gua

iano

lides

*Vi

guie

ra g

ardn

eri

+—

—10

7H

elen

alin

*A

rnic

ae s

pp.;

Hel

eniu

m a

rom

atic

um+

——

108

Hyp

oest

oxid

eH

ypoe

stes

ros

ea+

——

109,

110

Kam

ebac

etal

A*

Isod

on (

Rab

dosi

a) s

pp.

+—

—10

0K

ameb

akau

rin

Isod

on (

Rab

dosi

a) s

pp.

+—

—10

0K

aure

nic

acid

*Si

deri

tis

spp.

ent-

kaur

-16-

ene-

19-o

ic a

cid

+—

—10

1L

imon

ene

Citr

us f

ruits

Cit

rus

spp.

4-Is

opro

peny

l-1-

met

hyl-

1-cy

cloh

exan

e—

++

111

AU

: Is

this

co

mpl

ete?



TAB

LE 2

1.1

(con

tinu

ed)

Nat

ural

Pro

duct

s fr

om P

lant

s th

at E

xhib

it C

hem

opre

vent

ive

and

Ther

apeu

tic

Act

ivit

ies

agai

nst

Can

cer

Com

poun

dSo

urce

Bot

anic

al N

ame

Stru

ctur

e↓↓↓↓ N

F-κκκκ B

PT

Ref

.

Lin

earo

l*Si

deri

tis

spp.

+—

—10

1L

utei

nTo

mat

oLy

cope

rsic

on e

scul

entu

m—

——

112,

113

Lyco

pene

Tom

ato

Lyco

pers

icon

esc

ulen

tum

ψ,ψ

-Car

oten

e—

——

112–

114

Ole

andr

in*

Ner

ium

ole

ande

r; P

lum

eria

obs

ta+

——

115

Oxo

acan

thos

perm

olde

skM

ille

ria

quin

quefl

ora

+—

—11

6Pa

rthe

nolid

e*Fe

verf

ewTa

nace

tum

par

then

ium

and

T.

larv

atum

; M

iche

lia

cham

paca

; Ta

laum

a ov

at; M

agno

lia

gran

diflo

ra;

Art

emis

ia m

yria

ntha

+—

—11

7,11

8

Pris

timer

in*

Hip

pocr

atea

spp

.; M

ayte

nus

spp.

;Cel

astr

us o

rbic

ulat

us;

Rei

ssan

tia

buch

anan

ii;

Sala

cia

bedd

omei

; H

eist

eria

pal

lida

+—

—11

9

Tri

ptol

ide*

* (P

G 4

90)

Trip

tery

gium

wil

ford

ii+

——

120,

121

Urs

olic

aci

d*B

asil,

ros

emar

y, b

erri

esR

osm

arin

us o

ffici

nali

s; O

cim

um

sanc

tum

; A

roni

a m

elan

ocar

pa;

Oxy

cocc

us q

uadr

ipet

alus

; Ori

ganu

m

maj

oran

a; D

iosp

yros

mel

anox

ylon

; Sa

lvia

prz

ewal

skii

Max

im

+—

—12

2

With

anol

ides

Sola

nace

aeW

itha

nia

spp.

; P

hysa

lis

angu

lata

; So

rpic

hroa

ori

gani

foli

a—

——

123,

124

AU

: Wha

t do

es th

is

sym

bol i

ndi-

cate

?

AU

: Is

this

co

rrec

t?

AU

: Sho

uld

this

be

“Sal

-pi

chro

a”?



Alk

aloi

dsC

apsa

icin

oids

*l

Pepp

er,

red

chill

i, pa

prik

a fr

uits

Cap

sicu

m s

pp.

8-M

ethy

l-N

-van

illyl

-tra

ns-6

-no

neam

ide

++

+12

5–12

7

Cep

hara

nthi

ne*

Step

hani

a ce

phar

anth

a+

——

128

Con

ophy

lline

*Ta

bern

aem

onta

na s

pp;,

Erv

atam

ia

mic

roph

ylla

+—

—12

9

Hig

enam

ine

Ran

uncu

lace

aeA

coni

tum

jap

onic

um;

Arg

emon

e m

exic

ana;

Gne

tum

par

vifo

lium

Ben

zyl-

tetr

ahyd

rois

oqui

nolin

e al

kalo

id—

——

130,

131

Mah

anim

bine

Rut

acea

eM

urra

ya k

oeni

gii;

Cla

usen

a du

nnia

na;

Mur

raya

sia

men

sis

—+

—13

2,13

3

Mah

anin

eR

utac

eae

Mur

raya

koe

nigi

; M

icro

mel

um

min

utum

——

—13

2

Mor

phin

e m

and

its

an

alog

s O

pium

pop

pyPa

pave

r sp

p.

+—

+13

4–13

6

Mur

raya

nol

Rut

acea

eM

urra

ya k

oeni

gii

——

—13

3Pi

peri

neB

lack

pep

per

Gar

cini

a xa

ntho

chym

us;

Pip

er s

pp.

——

—11

5,13

7R

ocag

lam

ides

*A

glai

a sp

p.+

——

138

Tetr

andi

ne*

(sin

omen

ine

A)

Step

hani

a te

tran

dra

+—

—13

9

Thi

onia

div

ersi

foli

a ex

t.T

htio

nia

dive

rsif

olia

—

——

140,

141

Ally

lthi

osul

fina

teA

llici

nG

arlic

All

ium

sat

ivum

2-Pr

open

e-1-

sulfi

noth

ioic

aci

d-S-

2-pr

open

yl e

ster

——

—14

2,14

3

Ben

z[a]

phen

azin

eL

apac

hone

Gin

seng

, la

pach

o tr

ee,

trun

kwoo

dTa

bebu

ia s

pp.

++

+21



TAB

LE 2

1.1

(con

tinu

ed)

Nat

ural

Pro

duct

s fr

om P

lant

s th

at E

xhib

it C

hem

opre

vent

ive

and

Ther

apeu

tic

Act

ivit

ies

agai

nst

Can

cer

Com

poun

dSo

urce

Bot

anic

al N

ame

Stru

ctur

e↓↓↓↓ N

F-κκκκ B

PT

Ref

.

Ben

zopy

rene

Rot

enon

eD

erri

s sp

p.+

——

144

Caf

feic

aci

d ph

enyl

ethy

l es

ter

CA

PEH

oney

bee

pro

polis

Api

s m

elli

fera

cap

ensi

s+

——

21

Chl

orop

hyll

Cat

abol

ite

Pheo

phor

bide

ASo

lanu

m d

iflor

um+

——

145

Glu

cosi

nola

teSu

lpho

raph

ane

Bra

ssic

acea

e, e

.g.,

broc

coli,

cau

liflow

erB

rass

ica

oler

acea

4-

Met

hyls

ulph

inyl

but

yl -

isot

hioc

yana

te—

——

146

Indo

les

Indo

le-3

-car

bino

lB

rass

icac

eae,

e.g

., on

ions

, ca

bbag

e A

lliu

m c

epa;

Bra

ssic

a sp

p.3-

Indo

lem

etha

nol

——

—14

7

Irid

oid

glyc

osid

eA

ucub

in*

Alg

aeE

ucom

mia

spp

.; V

eron

ica

spp.

; Vi

tex

spp.

; G

lobu

lari

a sp

p.

+—

—14

8

Nap

toqu

inon

ePl

umba

gin

Plu

mba

go z

eyla

nica

5-H

ydro

xy-2

-met

hyl-

1,4-

naph

toqu

inon

e—

——

149

AU

: Wha

t do

es th

is

sym

bol i

ndi-

cate

?



Phen

yl P

ropa

noid

1′-A

ceto

xych

avic

ol

acet

ate

Zin

gibe

race

aeZ

ingi

ber

offic

inal

e; L

angu

as g

alan

ga—

——

28,1

50

Phen

olic

sE

thyl

gal

late

Gra

pes,

tea

, re

d m

aple

Paeo

nia

spp.

; So

phor

a ja

poni

ca; V

itis

vi

nife

ra;

Vite

llar

ia p

arad

oxa;

C

amel

lia

sine

nsis

+—

—15

1

Gal

lic a

cid*

Frui

ts,

e.g.

, gu

ava

Psi

dium

gua

java

; E

rodi

um

glau

coph

yllu

m;

Mel

aleu

ca

quin

quen

ervi

a

3,4,

5-T

rihy

drox

yben

zoic

aci

d—

+—

152

Gin

gero

lG

inge

rZ

ingi

ber

offic

inal

e (1

-[4′

-Hyd

roxy

-3′

met

hylp

heny

l-]-

5-hy

drox

y-3-

deca

ne

——

—15

3

Mor

ellin

Indi

ca f

ruit

Gar

cini

a sp

p.—

——

154

Spho

ndin

*H

erac

leum

lac

inia

tum

;Rut

a gr

aveo

lens

+—

—15

5

Phen

olic

Aci

dR

osem

arin

ic a

cid

Ros

emar

y, s

age

Ros

mar

inus

offi

cina

lis;

Sal

iva

offic

inal

is—

——

156

Syna

pic

acid

Sida

acu

ta4-

Hyd

roxy

-3,5

-di

met

hoxy

cinn

amic

aci

d—

——

157

Syri

ngic

aci

dR

adix

isa

tidi

s4-

Hyd

roxy

-3,5

-di

met

hoxy

benz

oic

acid

——

—15

8,15

9

Poly

sacc

hari

deG

anod

erm

a lu

cidu

m

ext.

Rei

shi

Gan

oder

ma

luci

dum

++

+16

0



TAB

LE 2

1.1

(con

tinu

ed)

Nat

ural

Pro

duct

s fr

om P

lant

s th

at E

xhib

it C

hem

opre

vent

ive

and

Ther

apeu

tic

Act

ivit

ies

agai

nst

Can

cer

Com

poun

dSo

urce

Bot

anic

al N

ame

Stru

ctur

e↓↓↓↓ N

F-κκκκ B

PT

Ref

.

Poly

isop

reny

late

d B

enzo

phen

one

Der

ivat

ives

Gar

cino

ln

and

its a

nalo

gs

Gar

cini

a in

dica

fru

it G

arci

nia

spp.

——

—16

1

Phyt

oale

xin

Alli

xin

Gar

licA

lliu

m s

ativ

um

3-H

ydro

xy-5

-met

hoxy

-6-

met

hyl-

2-pe

nthy

l-4h

-pyr

an-

4-on

e

——

—16

2

Sapo

nin

Cal

agua

line

Poly

podi

um s

pp.

+—

—16

3

Stilb

ene

Res

vera

trol

*o a

nd

anal

ogs

Japa

nese

kno

twee

d;

berr

y fr

uits

, . E

.gra

pes,

cr

anbe

rrie

s et

c.

Poly

gonu

m c

uspi

datu

m;

Vera

trum

sp

p.;

Viti

s sp

p.;

Vacc

inum

spp

.tr

ans-

3,4′

,5′-

Tri

hydr

oxys

tilbe

ne+

++

164–

166

Oth

ers

Age

d ga

rlic

ext

.G

arlic

All

ium

sat

ivum

+—

—16

7,16

8α-

lipoi

c ac

id*p

Asp

arag

us,

whe

at,

pota

toes

1,2-

Dith

iola

nepe

ntan

oic

acid

+—

—16

9–17

1

App

le e

xt.

(jui

ce)

App

le j

uice

Mal

us s

pp.

+—

—17

2A

stax

anth

in*

Mic

roal

ga,

alga

eH

aem

atoc

occu

s pl

uvia

lis

3,3′

-Dih

ydro

xy-β

,β,c

arot

ene-

4,4′

-dio

ne+

——

173

AU

: Wha

t do

es th

is

sym

bol i

ndi-

cate

?



β-G

luca

nB

arle

y, s

oy b

ean,

m

ushr

oom

Ave

na s

ativ

a; H

orde

um v

ulga

re;

Aga

ricu

s bl

azei

——

—17

4

β-si

tost

erol

Plan

ts,

nuts

, la

pach

a tr

ee,

cact

usG

lyci

ne m

ax;

Ara

chis

spp

.; M

icon

ia

rubi

gino

sa;

Opu

ntia

ficu

s-in

dica

α−D

ihyd

rofu

cost

erol

——

—17

5

Cat

’s c

law

Unc

aria

tom

ento

sa+

——

176

Cir

silin

eol

Bas

il, t

hym

eO

cim

um s

anct

um;

Lan

tana

m

onte

vide

nsis

Bri

q.;

Thy

mus

vu

lgar

is

——

—56

Dia

llyls

ulfid

eG

arlic

, C

hine

se l

eek

All

ium

sat

ivum

Dia

llyls

ulfid

e—

——

177

Flav

okaw

ains

(Kav

a la

cton

es)

Kav

a ka

vaP

iper

met

hyst

icum

——

—17

8

Ger

min

ated

bar

ley

+—

—17

9Pe

rsen

one

AA

voca

do P

erse

a am

eric

ana

1-(

Ace

tylo

xy)-

2-hy

drox

y-5,

12,1

5-he

neic

osat

rien

-4-o

ne

——

—18

0

Pom

egra

nate

win

eP

unic

a gr

anat

um—

——

181

S-al

lylc

yste

ine*

All

ium

sat

ivum

+—

—18

2St

ingi

ng n

ettle

ext

.U

rtic

a di

oica

——

—18

3T

rans

-Asa

rone

Car

rot

Dau

cus

caro

ta L

.tr

ans-

1-Pr

ophe

nyl-

2,4,

5-tr

imet

hoxy

benz

ene

——

—18

4

Vita

min

C*

Frui

ts a

nd v

eget

able

sA

scor

bic

acid

+—

—18

5,18

6V

itam

in E

Plan

t se

eds

and

vege

tabl

esα-

Toco

pher

ol+

——

187,

188

Not

e: T

and

P r

efer

to

ther

apy

and

prev

entio

n, r

espe

ctiv

ely;

the

ast

eris

k in

dica

tes

that

the

Che

mic

al s

truc

ture

is

show

n in

Fig

ure

21.2

(A

to

D).

aB

aica

lein

and

its

der

ivat

ives

inc

lude

bai

calin

, w

ogon

in,

and

wog

onin

, 6-

met

hoxy

-bai

cale

in (

orox

ylin

A).

bC

atec

hins

inc

lude

cat

echi

n, e

pica

tech

in,

epic

atec

hing

alla

te,

epig

allo

cate

chin

, an

d ep

igal

loca

tech

inga

llate

; th

eafla

vins

are

pol

yphe

nols

fou

nd i

n fe

rmen

ted

gree

nte

a, i

.e.,

blac

k te

a.c

Synt

hetic

com

poun

d cl

osel

y re

late

d to

a p

olyp

heno

l is

olat

ed f

rom

the

Ind

ian

plan

t, D

ysox

ylum

bin

ecta

rife

rum

.d

Glo

ssog

yne

tenu

ifol

ia i

s C

hine

se m

edic

ine

Hia

ng-j

u.

AU

: Wha

t do

the

blan

k sp

aces

indi

-ca

te?



TAB

LE 2

1.1

(con

tinu

ed)

Nat

ural

Pro

duct

s fr

om P

lant

s th

at E

xhib

it C

hem

opre

vent

ive

and

Ther

apeu

tic

Act

ivit

ies

agai

nst

Can

cer

eSi

lym

arin

inc

lude

s si

lybi

n, s

ilibi

nin,

sili

dian

, an

d si

lych

rist

.f

Ane

thol

and

ana

logs

inc

lude

eug

enol

, bi

s-eu

geno

l, is

oeug

enol

, an

d an

etho

ldith

iolth

ione

.g

Avi

cins

inc

lude

avi

cin

D a

nd a

vici

n G

.h

Aza

dira

chtin

ana

logs

inc

lude

axa

dira

chtin

A,B

, D

, H

, I,

etc

.i

Cur

cubu

taci

ns a

nalo

gs i

nclu

de c

urcu

bita

cin

B,

D,

E,

etc.

jG

erm

acra

nolid

es i

nclu

de 2

b,5-

epox

y-5,

10-d

ihyd

roxy

-6a-

ange

loyl

oxy-

9b-i

sobu

tylo

xy-g

erm

acra

n-8a

,12-

olid

e.k

Oxo

acan

thos

perm

olde

s in

clud

e m

etho

xym

iller

-9Z

-eno

lide.

lC

apsa

icin

oids

inc

lude

cap

saic

in*

and

anal

ogs,

e.g

., re

sini

fera

toxi

n* (

daph

neto

xin)

.m

Mor

phin

e an

d its

ana

logs

inc

lude

KT

90

and

sang

uina

rine

.n

Gar

cino

l an

d its

ana

logs

inc

lude

iso

garc

inol

.o

Res

vera

trol

and

ana

logs

inc

lude

pic

eata

nnol

.p

α-L

ipoi

c ac

id i

nclu

des

dihy

drol

ipoi

c ac

id.



that the synergies and additive effects of such treatments, coupled with their mildnature, allow for their safe use. The increase in the popularity and awareness ofcomplementary medicine has resulted in its use for the therapy of a variety ofhuman diseases and by a large percentage of cancer patients. For many suchpatients, the use of naturally derived plant compounds and plant extracts is anessential part of their treatment. In addition, people are now more aware of thehealth benefits associated with the use of natural products and plant-derivedcompounds and have turned to these because of the negative perceptions associ-ated with synthetic compounds. Most of the compounds outlined in Table 21.1are commonly used in the form of concentrated plant extracts, and combinations

FIGURE 21.2A Structure of some plant-derived polyphenols that block NF-κB.

OHO

HO

O

OOH

O

O

OHO

OHHO

Catalposide

OMeOH

OO

OMeHO

Curcumin I

OHAc

OHMeOCH2

OHO

AcOH

O

OH

OH

RHO

O

OOH

HO

HO

OH

O

O

OH

OH

Amentoflavone

OH3C O

H3C O

O OH

OCH3

Arctigenin

O

HO

Cannabinol

O

OHHO Pr

O

Carnosol

OOH

HO O

OH

Genistein

OO

HO

OH

HMP(hydroxymethoxyphenyl-phenylheptenone)

OH

HO

O

O

OH

OH

Emodin

Isomallatochromanol

O

O

OHOH

OHHO

OH

OHOH

OHO

EGCG(epigallocatechin gallate)

RPiceatannol OH

Resveratrol -

HO

OOH

OH

OH

Hematein

O

O

OH

OHO

O

HO

HO

Ellagic Acid

O

N

CH3

OH

HO

OH O

Cl

Flavopiridol

O

O

Lapachone



FIGURE 21.2B Structure of some plant-derived terpenoids that block NF-κB.

OR O

MeO OMe

OOH

OMe

OMe

R1 R2 R3 R4Apigenin

- - OH -

BaicaleinOH - - -

Luteolin- - OH OH

Oroxylin-AOCH3 - - -

Wogonin - OCH3 - -

OOH

HO O

R3

R1

R4

R2

R

Mana-ssantin A

CHMeCH(OH) O

OMe

Mana-ssantin B

C HMeC H(OH)

O

O

Saucerneol H

OH

HO O

OCO

OH

OH

OH

OH

HO OOH

O

OH

OH

O

O

OHOH

OH

Theaflavin-3,3-digallate

O

HO

HO

O

O

HO OMe

Wedelolactone

O HO O O

OMeOH

O

OPh

H2C

O

Resinferatoxin

HO OH

O

OH

HO HO

OH

O

O OH

CMe2

OH

Sanggenon C

OH

MeO OH

O

Ph

C Me2

Panduratin A

OHHO

OHOH

Nordihydroguaiaritic acid

O

O

O

OMeHO

HO

OHO

OH

OH

Silybin



FIGURE 21.2C Structure of some plant-derived alkaloids that block NF-κB.

HO

C H2H2C

OHOH

Andalusol

O O

Costunolide

O

HO

HO

OH

O

HO

HO

HO

O

OHHO

OO

O

COOHOH

OH

O

O

OHOH

OHC OOH

C OOH

Glycyrrhizin

O

O

O

O

O

OH

OH

Pr-i

O

O

Germacran-8 ,12-olide

-

H3C O

C H=CHMe

Anethole

O

O

OHOHO

OH

O

OHO

OHOH

OH

O

R

OH

O

O

OH

OH

OOH

O

OH

Avicin D

HO

C OOH

Betulinic acid

HO

O

HOOC

Celastrol

HO

C H2

C Me2

Bakuchiol

OMe

OAc

MeO O

Ergolide

OH

OH

OH

OHo

Excisanin A

OHHO

HO

Foliol

Ginsenoside

O O

C H2

OH

OC H2

O

C H2

C HOMeO

Methoxymillerenolide

OO

O

O

O

OH

Guaianolides

OMe

OH

MeO O

Helenalin

OH

OO

OH

OMe

Kamebacetal A

HO

H

O

OH

H

Ursolic acid

O

O

O

i-P rOH

O

O

Triptolide

OOHHOOC

Kaurenic acid

HO

AcOMe

OH

Linearol

OHO

MeO O

OAc

OO

OH

Oleandrin

O

HO

O

Pristimerin

O

OH

Eugenol

OH

O

Isoeugenol



of these extracts can be very complex. However, although humans have beenusing complex mixtures for much longer than they have been using single isolatedcompounds or drugs, there is a need for careful standardization of dietary sup-plements and effective regulatory control to ensure human safety.

ACKNOWLEDGMENTS

We would like to thank Walter Pagel for a careful review of the manuscript. Thecontributions of Aggarwal, a Ransom Horne, Jr., Distinguished Professor ofCancer Research, have been supported by the Clayton Foundation for Research,

FIGURE 21.2D Structure of some plant-derived miscellaneous compounds that blockNF-κB.

OHMeO

MeOHN

MeOOC

N

E tOH

ONH

N

O

E t

C OOMe

MeO

O

NMe

OO

O

NMe

OMe

Cepharanthine

N OMeO

N

MeO

OMe

O

OMe

Tetrandine

OHO OH

NMe

Morphine

Rocaglamide

OHN

OH

O

Capsaicin

Conophylline

O

OH

NMe2

O

OHOMe

MeOPh

OMe

C HO

HNHO

OH

Erbstatin

O

O

OO

MeN

Sanguinarine


AU: Pls. provide captiofor Fig. 21.2E.


a Department of Defense U.S. Army Breast Cancer Research Program grant(BC010610), a PO1 grant (CA91844) from the National Institutes of Health onlung chemoprevention, and a P50 Head and Neck SPORE grant from the NationalInstitutes of Health.

ABBREVIATIONS

IκBα: inhibitory subunit of NF-κBIKK: IκB kinase

FIGURE 21.2E

O

HO

HO

HOOH

OHO

O

OHAucubin

SS

O

OH

-lipoic acid

O OH

-tocopherol HO O

Astaxanthin

COOEt

OHHO

HO

O O

OMe

O

Sphondin

OH

OH

HO

OO

HO

Vitamin C

Ethylgallate

HO

HO

HOO

OH

Gallic acid

O

O

Ph

OH

HO

CAPE(caffeic acid phenylethyl ester)

-n


AU: Update?


REFERENCES

1. Garg A, Aggarwal BB. Nuclear transcription factor-κB as a target for cancer drugdevelopment. Leukemia 2002; 16: 1053–1068.

2. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-κ B: Its role inhealth and diseases. J Mol Med 2004(in press).

3. Shishodia S, Aggarwal BB. Nuclear factor (NF)-κB regulates the expression ofgenes involved in transformation, proliferation, invasion, angiogenesis andmetastasis of cancer. In Molecular Targeting and Signal Transduction. Ed:, RakeshKumar PD; 2003; Kluwer Publishers: Belgium.

4. Lin A, Karin M. NF-κB in cancer: a marked target. Semin Cancer Biol 2003; 13:107–114.

5. Orlowski RZ, Baldwin AS, Jr. NF-κB as a therapeutic target in cancer. TrendsMol Med 2002; 8: 385–389.

6. Valen G, Yan ZQ, Hansson GK. Nuclear factor κ-B and the heart. J Am CollCardiol 2001; 38: 307–314.

7. Jones WK, Brown M, Ren X, He S, McGuinness M. NF-κB as an integrator ofdiverse signaling pathways: the heart of myocardial signaling? Cardiovasc Toxicol2003; 3: 229–254.

8. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-κBaxis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord2003; 27 Suppl. 3: S49–52.

9. Yang L, Cohn L, Zhang DH, Homer R, Ray A, Ray P. Essential role of nuclearfactor κB in the induction of eosinophilia in allergic airway inflammation. J ExpMed 1998; 188: 1739–1750.

10. Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A. A critical role for NF-κB inGATA3 expression and TH2 differentiation in allergic airway inflammation. NatImmunol 2001; 2: 45–50.

11. Gagliardo R, Chanez P, Mathieu M, et al. Persistent activation of nuclear factor-κB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med2003; 168: 1190-1198.

12. Roshak AK, Callahan JF, Blake SM. Small-molecule inhibitors of NF-κB for thetreatment of inflammatory joint disease. Curr Opin Pharmacol 2002; 2: 316–321.

13. van Heel DA, Udalova IA, De Silva AP, et al. Inflammatory bowel disease isassociated with a TNF polymorphism that affects an interaction between the OCT1and NF(-κ)B transcription factors. Hum Mol Genet 2002; 11: 1281-1289.

14. Huang CJ, Nazarian R, Lee J, Zhao PM, Espinosa-Jeffrey A, de Vellis J. Tumornecrosis factor modulates transcription of myelin basic protein gene throughnuclear factor κB in a human oligodendroglioma cell line. Int J Dev Neurosci2002; 20: 289–296.

15. Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegener-ative disorders. J Clin Invest 2001; 107: 247–254.

16. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcriptionfactor NF-κB is activated in primary neurons by amyloid beta peptides and inneurons surrounding early plaques from patients with Alzheimer disease. ProcNatl Acad Sci USA 1997; 94: 2642-2647.

17. Burke JR. Targeting I kappa B kinase for the treatment of inflammatory and otherdisorders. Curr Opin Drug Discov Dev 2003; 6: 720–728.



18. Yamamoto Y, Gaynor RB. Role of the NF-κB pathway in the pathogenesis ofhuman disease states. Curr Mol Med 2001; 1: 287–296.

19. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB path-way in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135–42.

20. Shobana S, Naidu KA. Antioxidant activity of selected Indian spices. Prostaglan-dins Leukot Essent Fatty Acids 2000; 62: 107–110.

21. Natarajan K, Singh S, Burke TR, Jr., Grunberger D, Aggarwal BB. Caffeic acidphenethyl ester is a potent and specific inhibitor of activation of nuclear transcrip-tion factor NF-κB. Proc Natl Acad Sci USA 1996; 93: 9090–9095.

22. Banerjee T, Valacchi G, Ziboh VA, van der Vliet A. Inhibition of TNFalpha-induced cyclooxygenase-2 expression by amentoflavone through suppression ofNF-κB activation in A549 cells. Mol Cell Biochem 2002; 238: 105-110.

23. Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factor-κB, Bax and Bcl-2in induction of cell cycle arrest and apoptosis by apigenin in human prostatecarcinoma cells. Oncogene 2002; 21: 3727–3738.

24. Shukla S, Gupta S. Molecular mechanisms for apigenin-induced cell-cycle arrestand apoptosis of hormone refractory human prostate carcinoma DU145 cells. MolCarcinog 2004; 39: 114–126.

25. Choi JS, Choi YJ, Park SH, Kang JS, Kang YH. Flavones mitigate tumor necrosisfactor-alpha-induced adhesion molecule upregulation in cultured human endothe-lial cells: role of nuclear factor-kappaB. J Nutr 2004; 134: 1013–1019.

26. Kang BY, Chung SW, Kim SH, Cho D, Kim TS. Involvement of nuclear factor-kappaB in the inhibition of interleukin-12 production from mouse macrophagesby baicalein, a flavonoid in Scutellaria baicalensis. Planta Med 2003; 69: 687–691.

27. Cho MK, Park JW, Jang YP, Kim YC, Kim SG. Potent inhibition of lipopolysac-charide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lig-nans through inhibition of I-κBα phosphorylation and of p65 nuclear translocationin macrophages. Int Immunopharmacol 2002; 2: 105–116.

28. Murakami A, Matsumoto K, Koshimizu K, Ohigashi H. Effects of selected foodfactors with chemopreventive properties on combined lipopolysaccharide- andinterferon-gamma-induced IκB degradation in RAW264.7 macrophages. CancerLett 2003; 195: 17–25.

29. Krakauer T, Li BQ, Young HA. The flavonoid baicalin inhibits superantigen-induced inflammatory cytokines and chemokines. FEBS Lett 2001; 500: 52–55.

30. Kim H, Kim YS, Kim SY, Suk K. The plant flavonoid wogonin suppresses deathof activated C6 rat glial cells by inhibiting nitric oxide production. Neurosci Lett2001; 309: 67–71.

31. Chen Y-C, Shen S-C, Hsu F-L. Biological activities of flavonoids. In: OrientalFoods and Herbs, ACS Symposium Series, 2003; Vol. 859.

32. Huang C, Huang Y, Li J, et al. Inhibition of benzo(a)pyrene diol-epoxide-inducedtransactivation of activated protein 1 and nuclear factor κB by black raspberryextracts. Cancer Res 2002; 62: 6857–6863.

33. Atalay M, Gordillo G, Roy S, et al. Anti-angiogenic property of edible berry ina model of hemangioma. FEBS Lett 2003; 544: 252–7.

34. Kresty LA, Morse MA, Morgan C, et al. Chemoprevention of esophageal tumor-igenesis by dietary administration of lyophilized black raspberries. Cancer Res2001; 61: 6112–6119.


AU: Not citedin the text ortable.


35. Herring AC, Koh WS, Kaminski NE. Inhibition of the cyclic AMP signalingcascade and nuclear factor binding to CRE and kappaB elements by cannabinol,a minimally CNS-active cannabinoid. Biochem Pharmacol 1998; 55: 1013–1023.

36. Herring AC, Kaminski NE. Cannabinol-mediated inhibition of nuclear factor-κB,cAMP response element-binding protein, and interleukin-2 secretion by activatedthymocytes. J Pharmacol Exp Ther 1999; 291: 1156–1163.

37. Hollister LE. Interactions of marijuana and THC with other drugs: what we don’t,but should know, Marihuana and Medicine, New York, March 20–21, 1998.

38. An SJ, Pae HO, Oh GS, et al. Inhibition of TNF-alpha, IL-1beta, and IL-6productions and NF-κB activation in lipopolysaccharide-activated RAW 264.7macrophages by catalposide, an iridoid glycoside isolated from Catalpa ovata G.Don (Bignoniaceae). Int Immunopharmacol 2002; 2: 1173–1181.

39. Mackenzie GG, Carrasquedo F, Delfino JM, Keen CL, Fraga CG, Oteiza PI.Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-κBactivation at multiple steps in Jurkat T cells. FASEB J 2004; 18: 167–169.

40. Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. Green tea polyphenol epigal-locatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformedphenotype of breast cancer cells. Cancer Res 2002; 62: 652–655.

41. Pan MH, Lin-Shiau SY, Ho CT, Lin JH, Lin JK. Suppression of lipopolysaccharide-induced nuclear factor-kappaB activity by theaflavin-3,3′-digallate from black teaand other polyphenols through down-regulation of IκB kinase activity in mac-rophages. Biochem Pharmacol 2000; 59: 357–367.

42. Ibanez E, Kubatova A, Senorans FJ, Cavero S, Reglero G, Hawthorne SB. Sub-critical water extraction of antioxidant compounds from rosemary plants. J AgricFood Chem 2003; 51: 375–382.

43. van’t Land B, Blijlevens NM, Marteijn J, et al. Role of curcumin and the inhibitionof NF-κB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia2004; 18: 276–284.

44. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemopreventionof colon carcinogenesis by dietary administration of piroxicam, alpha-difluoro-methylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individuallyand in combination. Cancer Res 1991; 51: 4528–4534.

45. Kumar A, Dhawan S, Aggarwal BB. Emodin (3-methyl-1,6,8-trihydroxyanthra-quinone) inhibits TNF-induced NF-kappaB activation, IκB degradation, andexpression of cell surface adhesion proteins in human vascular endothelial cells.Oncogene 1998; 17: 913–918.

46. Takada Y, Aggarwal BB. Flavopiridol inhibits NF-kappaB activation induced byvarious carcinogens and inflammatory agents through inhibition of IκBα kinaseand p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrixmetalloprotease-9. J Biol Chem 2004; 279: 4750–4759.

47. Muraoka K, Shimizu K, Sun X, et al. Flavonoids exert diverse inhibitory effectson the activation of NF-kappaB. Transplant Proc 2002; 34: 1335–1340.

48. Gong L, Li Y, Nedeljkovic-Kurepa A, Sarkar FH. Inactivation of NF-κB bygenistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene2003; 22: 4702–4709.

49. Wu MJ, Wang L, Ding HY, Weng CY, Yen JH. Glossogyne tenuifolia acts to inhibitinflammatory mediator production in a macrophage cell line by downregulatingLPS-induced NF-κB. J Biomed Sci 2004; 11: 186–199.



50. Choi JH, Jeong TS, Kim DY, et al. Hematein inhibits atherosclerosis by inhibitionof reactive oxygen generation and NF-κB-dependent inflammatory mediators inhyperlipidemic mice. J Cardiovasc Pharmacol 2003; 42: 287–295.

51. Hong JJ, Jeong TS, Choi JH, et al. Hematein inhibits tumor necrotic factor-alpha-induced vascular cell adhesion molecule-1 and NF-kappaB-dependent geneexpression in human vascular endothelial cells. Biochem Biophys Res Commun2001; 281: 1127–1133.

52. Behar A, Pujade-Lauraine E, Maurel A, et al. The pathophysiological mechanismof fluid retention in advanced cancer patients treated with docetaxel, but notreceiving corticosteroid comedication. Br J Clin Pharmacol 1997; 43: 653–658.

53. Yadav PN, Liu Z, Rafi MM. A diarylheptanoid from lesser galangal (Alpiniaofficinarum) inhibits proinflammatory mediators via inhibition of mitogen-activatedprotein kinase, p44/42, and transcription factor nuclear factor-κB. J PharmacolExp Ther 2003; 305: 925–931.

54. Bork PM, Bacher S, Schmitz ML, Kaspers U, Heinrich M. Hypericin as a non-antioxidant inhibitor of NF-κB. Planta Med 1999; 65: 297–300.

55. Agostinis P, Vantieghem A, Merlevede W, de Witte PA. Hypericin in cancertreatment: more light on the way. Int J Biochem Cell Biol 2002; 34: 221–241.

56. Kelm MA, Nair MG, Strasburg GM, DeWitt DL. Antioxidant and cyclooxygenaseinhibitory phenolic compounds from Ocimum sanctum Linn. Phytomedicine 2000;7: 7–13.

57. Ishii R, Horie M, Saito K, Arisawa M, Kitanaka S. Inhibition of lipopolysaccha-ride-induced pro-inflammatory cytokine expression via suppression of nuclearfactor-κB activation by Mallotus japonicus phloroglucinol derivatives. BiochimBiophys Acta 2003; 1620: 108–118.

58. Lombardi-Boccia G, Lucarini M, Lanzi S, Aguzzi A, Cappelloni M. Nutrients andantioxidant molecules in yellow plums (Prunus domestica L.) from conventionaland organic productions: a comparative study. J Agric Food Chem 2004; 52: 90–94.

59. Kim SH, Shin KJ, Kim D, et al. Luteolin inhibits the nuclear factor-kappa Btranscriptional activity in Rat-1 fibroblasts. Biochem Pharmacol 2003; 66: 955–963.

60. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implicationsfor the prevention and therapeutics of Alzheimer’s disease. J Neurochem 2003;87: 172–181.

61. Hollman PC, Katan MB. Health effects and bioavailability of dietary flavonols.Free Radic Res 1999; 31 Suppl.: S75–80.

62. Noda Y, Kneyuki T, Igarashi K, Mori A, Packer L. Antioxidant activity of nasunin,an anthocyanin in eggplant peels. Toxicology 2000; 148: 119–23.

63. Brennan P, O’Neill LA. Inhibition of nuclear factor kappaB by direct modificationin whole cells — mechanism of action of nordihydroguaiaritic acid, curcumin andthiol modifiers. Biochem Pharmacol 1998; 55: 965–973.

64. Tang S, Bremner P, Kortenkamp A, et al. Biflavonoids with cytotoxic and anti-bacterial activity from Ochna macrocalyx. Planta Med 2003; 69: 247–253.

65. Aoki K, Maruta H, Uchiumi F, Hatano T, Yoshida T, Tanuma S. A macrocircularellagitannin, oenothein B, suppresses mouse mammary tumor gene expression viainhibition of poly(ADP-ribose) glycohydrolase. Biochem Biophys Res Commun1995; 210: 329–337.



66. Yun JM, Kwon H, Hwang JK. In vitro anti-inflammatory activity of panduratinA isolated from Kaempferia pandurata in RAW264.7 cells. Planta Med 2003; 69:1102–1108.

67. Llopiz N, Puiggros F, Cespedes E, et al. Antigenotoxic effect of grape seedprocyanidin extract in fao cells submitted to oxidative stress. J Agric Food Chem2004; 52: 1083–1087.

68. Wu TW, Zeng LH, Wu J, et al. Molecular structure and antioxidant specificity ofpurpurogallin in three types of human cardiovascular cells. Biochem Pharmacol1996; 52: 1073-1080.

69. O’Coinceanainn M, Astill C, Baderschneider B. Coordination of aluminium withpurpurogallin and theaflavin digallate. J Inorg Biochem 2003; 96: 463–468.

70. Peng Q, Wei Z, Lau BH. Pycnogenol inhibits tumor necrosis factor-alpha-inducednuclear factor kappa B activation and adhesion molecule expression in humanvascular endothelial cells. Cell Mol Life Sci 2000; 57: 834–841.

71. Packer L. Antioxidant and biological activity of a French maritime pine-barkextract. 219th ACS National Meeting, 2000.

72. Cho SY, Park SJ, Kwon MJ, et al. Quercetin suppresses proinflammatory cytokinesproduction through MAP kinases and NF-κB pathway in lipopolysaccharide-stimulated macrophage. Mol Cell Biochem 2003; 243: 153–160.

73. Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP. Rhein inhibitsinterleukin-1β-induced activation of MEK/ERK pathway and DNA binding ofNF-κB and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism forits disease-modifying effect in osteoarthritis. Inflammation 2003; 27: 233–246.

74. Li LC, Shen F, Hou Q, Cheng GF. Inhibitory effect and mechanism of action ofsanggenon C on human polymorphonuclear leukocyte adhesion to human synovialcells. Acta Pharmacol Sin 2002; 23: 138–142.

75. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutiveand TNFα-induced activation of NF-κB and sensitizes human prostate carcinomaDU145 cells to TNFα-induced apoptosis. Oncogene 2002; 21: 1759–1767.

76. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-κB, c-Jun N-terminal kinase, and apoptosis. J Immunol1999; 163: 6800–6809.

77. Gallo D, Giacomelli S, Ferlini C, et al. Antitumour activity of the silybin-phos-phatidylcholine complex, IdB 1016, against human ovarian cancer. Eur J Cancer2003; 39: 2403–2410.

78. Hwang BY, Lee JH, Nam JB, Hong YS, Lee JJ. Lignans from Saururus chinensisinhibiting the transcription factor NF-kappaB. Phytochemistry 2003; 64: 765–771.

79. Hwang BY, Lee JH, Jung HS, et al. Sauchinone, a lignan from Saururus chinensis,suppresses iNOS expression through the inhibition of transactivation activity ofRelA of NF-κB. Planta Med 2003; 69: 1096–1101.

80. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamox-ifen’s therapeutic benefit in mammary cancer. J Natl Cancer Inst 1999; 91: 354–359.

81. Kobori M, Yang Z, Gong D, et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ 2004;11: 123–130.

82. Chun KS, Kang JY, Kim OH, Kang H, Surh YJ. Effects of yakuchinone A andyakuchinone B on the phorbol ester-induced expression of COX-2 and iNOS andactivation of NF-kappaB in mouse skin. J Environ Pathol Toxicol Oncol 2002;21: 131–139.



83. de las Heras B, Navarro A, Diaz-Guerra MJ, et al. Inhibition of NOS-2 expressionin macrophages through the inactivation of NF-κB by andalusol. Br J Pharmacol1999; 128: 605–612.

84. Chainy GB, Manna SK, Chaturvedi MM, Aggarwal BB. Anethole blocks bothearly and late cellular responses transduced by tumor necrosis factor: effect onNF-κB, AP-1, JNK, MAPKK and apoptosis. Oncogene 2000; 19: 2943–2950.

85. Murakami Y, Shoji M, Hanazawa S, Tanaka S, Fujisawa S. Preventive effect ofbis-eugenol, a eugenol ortho dimer, on lipopolysaccharide-stimulated nuclearfactor κB activation and inflammatory cytokine expression in macrophages. Bio-chem Pharmacol 2003; 66: 1061–1066.

86. Aldieri E, Atragene D, Bergandi L, et al. Artemisinin inhibits inducible nitric oxidesynthase and nuclear factor NF-κB activation. FEBS Lett 2003; 552: 141–144.

87. Haridas V, Arntzen CJ, Gutterman JU. Avicins, a family of triterpenoid saponinsfrom Acacia victoriae (Bentham), inhibit activation of nuclear factor-kappaB byinhibiting both its nuclear localization and ability to bind DNA. Proc Natl AcadSci USA 2001; 98: 11557–11562.

88. Akudugu J, Gade G, Bohm L. Cytotoxicity of azadirachtin A in human glioblas-toma cell lines. Life Sci 2001; 68: 1153–1160.

89. Adom KK, Sorrells ME, Liu RH. Phytochemical profiles and antioxidant activityof wheat varieties. J Agric Food Chem 2003; 51: 7825–7834.

90. Prakash P, Liu C, Hu KQ, Krinsky NI, Russell RM, Wang XD. Beta-carotene andbeta-apo-14′-carotenoic acid prevent the reduction of retinoic acid receptor betain benzo[a]pyrene-treated normal human bronchial epithelial cells. J Nutr 2004;134: 667–673.

91. Uchiyama S, Yamaguchi M. Inhibitory effect of beta-cryptoxanthin on osteoclast-likecell formation in mouse marrow cultures. Biochem Pharmacol 2004; 67: 1297–1305.

92. Pae HO, Cho H, Oh GS, et al. Bakuchiol from Psoralea corylifolia inhibits theexpression of inducible nitric oxide synthase gene via the inactivation of nucleartranscription factor-kappaB in RAW 264.7 macrophages. Int Immunopharmacol2001; 1: 1849–1855.

93. Takada Y, Aggarwal BB. Betulinic acid suppresses carcinogen-induced NF-kappaB activation through inhibition of I kappa B alpha kinase and p65 phosphorylation:abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol 2003;171: 3278–3286.

94. Lo AH, Liang YC, Lin-Shiau SY, Ho CT, Lin JK. Carnosol, an antioxidant inrosemary, suppresses inducible nitric oxide synthase through down-regulatingnuclear factor-κB in mouse macrophages. Carcinogenesis 2002; 23: 983–991.

95. Jin HZ, Hwang BY, Kim HS, Lee JH, Kim YH, Lee JJ. Antiinflammatory con-stituents of Celastrus orbiculatus inhibit the NF-κB activation and NO production.J Nat Prod 2002; 65: 89–91.

96. Koo TH, Lee JH, Park YJ, et al. A sesquiterpene lactone, costunolide, fromMagnolia grandiflora inhibits NF-κB by targeting I κB phosphorylation. PlantaMed 2001; 67: 103–107.

97. Sun IC, Kashiwada Y, Morris-Natschke SL, Lee KH. Plant-derived terpenoids andanalogues as anti-HIV agents. Curr Top Med Chem 2003; 3: 155–169.

98. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator oftranscription 3 signaling pathway inhibitor with potent antitumor activity againsthuman and murine cancer cells in mice. Cancer Res 2003; 63: 1270–1279.



99. Whan Han J, Gon Lee B, Kee Kim Y, et al. Ergolide, sesquiterpene lactone fromInula britannica, inhibits inducible nitric oxide synthase and cyclo-oxygenase-2expression in RAW 264.7 macrophages through the inactivation of NF-kappaB.Br J Pharmacol 2001; 133: 503–512.

100. Hwang BY, Lee JH, Koo TH, et al. Kaurane diterpenes from Isodon japonicusinhibit nitric oxide and prostaglandin E2 production and NF-κB activation in LPS-stimulated macrophage RAW264.7 cells. Planta Med 2001; 67: 406–410.

101. Castrillo A, de Las Heras B, Hortelano S, Rodriguez B, Villar A, Bosca L. Inhibitionof the nuclear factor kappa B (NF-κB) pathway by tetracyclic kaurene diterpenes inmacrophages. Specific effects on NF-κB-inducing kinase activity and on the coordi-nate activation of ERK and p38 MAPK. J Biol Chem 2001; 276: 15854–15860.

102. Kim EJ, Jin HK, Kim YK, et al. Suppression by a sesquiterpene lactone fromCarpesium divaricatum of inducible nitric oxide synthase by inhibiting nuclearfactor-kappaB activation. Biochem Pharmacol 2001; 61: 903–910.

103. Muller S, Murillo R, Castro V, Brecht V, Merfort I. Sesquiterpene lactones fromMontanoa hibiscifolia that inhibit the transcription factor NF-κB. J Nat Prod 2004;67: 622–630.

104. Wei Z, Peng Q, Lau BH, Shah V. Ginkgo biloba inhibits hydrogen peroxide-induced activation of nuclear factor κB in vascular endothelial cells. Gen Phar-macol 1999; 33: 369–375.

105. Keum YS, Han SS, Chun KS, et al. Inhibitory effects of the ginsenoside Rg3 onphorbol ester-induced cyclooxygenase-2 expression, NF-κB activation and tumorpromotion. Mutat Res 2003; 523–524: 75–85.

106. Wang JY, Guo JS, Li H, Liu SL, Zern MA. Inhibitory effect of glycyrrhizin onNF-κB binding activity in CCl4- plus ethanol-induced liver cirrhosis in rats. Liver1998; 18: 180–185.

107. Schorr K, Garcia-Pineres AJ, Siedle B, Merfort I, Da Costa FB. Guaianolidesfrom Viguiera gardneri inhibit the transcription factor NF-κB. Phytochemistry2002; 60: 733–740.

108. Lyss G, Schmidt TJ, Merfort I, Pahl HL. Helenalin, an anti-inflammatory sesquit-erpene lactone from Arnica, selectively inhibits transcription factor NF-kappaB.Biol Chem 1997; 378: 951–961.

109. Ojo-Amaize EA, Kapahi P, Kakkanaiah VN, et al. Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IκB kinase. Cell Immunol2001; 209: 149–157.

110. Ojo-Amaize EA, Nchekwube EJ, Cottam HB, et al. Hypoestoxide, a naturalnonmutagenic diterpenoid with antiangiogenic and antitumor activity: possiblemechanisms of action. Cancer Res 2002; 62: 4007–4014.

111. Gould MN, Moore CJ, Zhang R, Wang B, Kennan WS, Haag JD. Limonenechemoprevention of mammary carcinoma induction following direct in situ trans-fer of v-Ha-ras. Cancer Res 1994; 54: 3540–3543.

112. Chew BP, Park JS. Carotenoid action on the immune response. J Nutr 2004; 134:257S–261S.

113. Khachik F, Beecher GR, Smith JC, Jr. Lutein, lycopene, and their oxidativemetabolites in chemoprevention of cancer. J Cell Biochem Suppl 1995; 22: 236–246.

114. Liu C, Lian F, Smith DE, Russell RM, Wang XD. Lycopene supplementationinhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. CancerRes 2003; 63: 3138–3144.



115. Selvendiran K, Senthilnathan P, Magesh V, Sakthisekaran D. Modulatory effectof Piperine on mitochondrial antioxidant system in Benzo(a)pyrene-inducedexperimental lung carcinogenesis. Phytomedicine 2004; 11: 85–89.

116. Castro V, Rungeler P, Murillo R, et al. Study of sesquiterpene lactones fromMilleria quinqueflora on their anti-inflammatory activity using the transcriptionfactor NF-κB as molecular target. Phytochemistry 2000; 53: 257–263.

117. Hehner SP, Heinrich M, Bork PM, et al. Sesquiterpene lactones specifically inhibitactivation of NF-kappa B by preventing the degradation of I kappa B-alpha andI kappa B-beta. J Biol Chem 1998; 273: 1288–1297.

118. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatorynatural product parthenolide from the medicinal herb Feverfew directly binds toand inhibits IκB kinase. Chem Biol 2001; 8: 759–766.

119. Dirsch VM, Kiemer AK, Wagner H, Vollmar AM. The triterpenoid quinonemethidepristimerin inhibits induction of inducible nitric oxide synthase in murine mac-rophages. Eur J Pharmacol 1997; 336: 211–217.

120. Sylvester J, Liacini A, Li WQ, Dehnade F, Zafarullah M. Tripterygium wilfordiiHook F extract suppresses proinflammatory cytokine-induced expression of matrixmetalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-κB activities. Mol Pharmacol 2001; 59: 1196–1205.

121. Qiu D, Kao PN. Immunosuppressove and anti-inflammatory mechanisms of trip-tolide, the principal active diterpenoid from the Chinese medicinal herb triptery-gium wilfordii Hook. f. Drugs in R&D 2003; 4: 1–18.

122. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB. Ursolic acid inhibits nuclearfactor-κB activation induced by carcinogenic agents through suppression of IκBαkinase and p65 phosphorylation: correlation with down-regulation of cyclo-oxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res 2003; 63:4375–4383.

123. Park EJ, Pezzuto JM. Botanicals in cancer chemoprevention. Cancer MetastasisRev 2002; 21: 231–255.

124. Misico RI, Song LL, Veleiro AS, et al. Induction of quinone reductase by witha-nolides. J Nat Prod 2002; 65: 677–680.

125. Sancho R, Lucena C, Macho A, et al. Immunosuppressive activity of capsaicinoids:capsiate derived from sweet peppers inhibits NF-kappaB activation and is a potentantiinflammatory compound in vivo. Eur J Immunol 2002; 32: 1753–1763.

126. Chen CW, Lee ST, Wu WT, Fu WM, Ho FM, Lin WW. Signal transduction forinhibition of inducible nitric oxide synthase and cyclooxygenase-2 induction bycapsaicin and related analogs in macrophages. Br J Pharmacol 2003; 140:1077–1087.

127. Singh S, Natarajan K, Aggarwal BB. Capsaicin (8-methyl-N-vanillyl-6-nonena-mide) is a potent inhibitor of nuclear transcription factor-κB activation by diverseagents. J Immunol 1996; 157: 4412–4420.

128. Okamoto M, Ono M, Baba M. Suppression of cytokine production and neural celldeath by the anti-inflammatory alkaloid cepharanthine: a potential agent againstHIV-1 encephalopathy. Biochem Pharmacol 2001; 62: 747–753.

129. Gohda J, Inoue J, Umezawa K. Down-regulation of TNF-α receptors by cono-phylline in human T-cell leukemia cells. Int J Oncol 2003; 23: 1373–1379.

130. Chang YC, Chang FR, Khalil AT, Hsieh PW, Wu YC. Cytotoxic benzophenan-thridine and benzylisoquinoline alkaloids from Argemone mexicana. Z Naturfor-sch [C] 2003; 58: 521–526.



131. Kang YJ, Lee YS, Lee GW, et al. Inhibition of activation of nuclear factor κB isresponsible for inhibition of inducible nitric oxide synthase expression by hige-namine, an active component of aconite root. J Pharmacol Exp Ther 1999; 291:314–320.

132. Tachibana Y, Kikuzaki H, Lajis NH, Nakatani N. Antioxidative activity of carba-zoles from Murraya koenigii leaves. J Agric Food Chem 2001; 49: 5589–5594.

133. Ramsewak RS, Nair MG, Strasburg GM, DeWitt DL, Nitiss JL. Biologically activecarbazole alkaloids from Murraya koenigii. J Agric Food Chem 1999; 47: 444–447.

134. Sueoka E, Sueoka N, Kai Y, et al. Anticancer activity of morphine and its syntheticderivative, KT-90, mediated through apoptosis and inhibition of NF-κB activation.Biochem Biophys Res Commun 1998; 252: 566–570.

135. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Hypogo-nadism and sexual dysfunction in male cancer survivors receiving chronic opioidtherapy. J Pain Symptom Manage 2003; 26: 1055–1061.

136. Chaturvedi MM, Kumar A, Darnay BG, Chainy GB, Agarwal S, Aggarwal BB.Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation,IκBα phosphorylation, and degradation. J Biol Chem 1997; 272: 30129–30134.

137. Rauscher FM, Sanders RA, Watkins JB, 3rd. Effects of piperine on antioxidantpathways in tissues from normal and streptozotocin-induced diabetic rats. J Bio-chem Mol Toxicol 2000; 14: 329–334.

138. Baumann B, Bohnenstengel F, Siegmund D, et al. Rocaglamide derivatives are potentinhibitors of NF-κB activation in T-cells. J Biol Chem 2002; 277: 44791–44800.

139. Ye J, Ding M, Zhang X, Rojanasakul Y, Shi X. On the role of hydroxyl radicaland the effect of tetrandrine on nuclear factor — kappaB activation by phorbol12-myristate 13-acetate. Ann Clin Lab Sci 2000; 30: 65–71.

140. Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M. Sesquiterpene lactonecontaining Mexican Indian medicinal plants and pure sesquiterpene lactones aspotent inhibitors of transcription factor NF-κB. FEBS Lett 1997; 402: 85

21 preventive and therapeutic effects of plant polyphenols through suppression of ... · 2014. 1....

Documents